SPI Pharma

spipharma.com

For over 75 years, we have supplied the pharmaceutical industry with highly engineered products and innovative solutions that improve the formulation and delivery of drug products to meet patient needs. Our functional excipients and active ingredients meet the highest-quality standards possible and can offer customized, cost-effective options for many applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIEWS AND ANALYSIS, PHARMACY MARKET

MEDRHYTHMS RECOGNIZED FOR ADVANCEMENTS IN PRESCRIPTION DIGITAL THERAPEUTICS FROM CB INSIGHTS, REUTERS EVENTS PHARMA AND FAST COMPANY

MedRhythms | December 12, 2022

news image

CB Insights today announced that, for the second year in a row, MedRhythms has been named to its annual Digital Health 150, a list that showcases the 150 most promising private digital health companies. This recognition comes a week after MedRhythms received the Most Valuable Digital Therapy award at the Reuters Events Pharma Awards ceremony and less than a month after MedRhythms was named a Fast Company Next Big Things in Tech honoree for the progress that the company has made on its products a...

Read More

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

news image

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More

Research

ROIVANT GROWS COMPUTATIONAL DRUG DISCOVERY ENGINE WITH ACQUISITION OF SILICON THERAPEUTICS

Roivant Sciences | March 01, 2021

news image

Silicon Therapeutics has assembled an exclusive industry-driving computational physics platform for the in silico design and optimization of small molecule drugs for testing disease targets. The platform incorporates custom strategies dependent on quantum mechanics, sub-atomic elements and measurable thermodynamics to beat basic bottlenecks in drug disclosure projects, for example, anticipating restricting energies and conformational conduct of molecules. Silicon Therapeutics'...

Read More

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

news image

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

MEDRHYTHMS RECOGNIZED FOR ADVANCEMENTS IN PRESCRIPTION DIGITAL THERAPEUTICS FROM CB INSIGHTS, REUTERS EVENTS PHARMA AND FAST COMPANY

MedRhythms | December 12, 2022

CB Insights today announced that, for the second year in a row, MedRhythms has been named to its annual Digital Health 150, a list that showcases the 150 most promising private digital health companies. This recognition comes a week after MedRhythms received the Most Valuable Digital Therapy award at the Reuters Events Pharma Awards ceremony and less than a month after MedRhythms was named a Fast Company Next Big Things in Tech honoree for the progress that the company has made on its products a...

Read More
news image

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More
news image

Research

ROIVANT GROWS COMPUTATIONAL DRUG DISCOVERY ENGINE WITH ACQUISITION OF SILICON THERAPEUTICS

Roivant Sciences | March 01, 2021

Silicon Therapeutics has assembled an exclusive industry-driving computational physics platform for the in silico design and optimization of small molecule drugs for testing disease targets. The platform incorporates custom strategies dependent on quantum mechanics, sub-atomic elements and measurable thermodynamics to beat basic bottlenecks in drug disclosure projects, for example, anticipating restricting energies and conformational conduct of molecules. Silicon Therapeutics'...

Read More
news image

Pharmacy Market

QUVA PHARMA EXPANDS RFID CAPABILITIES FOR ITS PRE-TAGGED, READY-TO-ADMINISTER INJECTABLES

PRNewswire | June 14, 2023

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format. "Insights from our customers and reports like ASHP's that assessed RFID utilization i...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us